Medifast (NYSE:MED) Issues Q2 2026 Earnings Guidance

Key Points

• Q2 2026 guidance: Medifast guided EPS of -1.00 to -0.50 (consensus -0.43) and revenue of $60M–$80M (consensus $75M), while updating FY2026 EPS to -2.75 to -1.55.
• Shares fell to $10.58 after the update; the company has a market cap of $116.8M, a negative P/E, and analysts carry an average rating of “Reduce” with a consensus price target of $12.00.
• Insider activity and ownership: CEO Daniel Chard bought 17,678 shares at $10.11, insiders own 3.7% of the stock, and institutional investors hold about 95.5%.

Medifast (NYSE:MED - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of -1.000--0.500 for the period, compared to the consensus estimate of -0.430. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $75.0 million. Medifast also updated its FY 2026 guidance to -2.750--1.550 EPS.

Medifast Stock Performance

NYSE MED traded down $0.33 on Monday, reaching $10.58. 150,459 shares of the company's stock traded hands, compared to its average volume of 241,666. Medifast has a fifty-two week low of $9.22 and a fifty-two week high of $15.46. The firm has a market cap of $116.76 million, a price-to-earnings ratio of -6.19 and a beta of 0.55. The stock has a 50 day moving average price of $10.41 and a 200-day moving average price of $11.10.

Medifast (NYSE:MED - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.36. The company had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.Medifast has set its FY 2026 guidance at -2.750--1.550 EPS and its Q2 2026 guidance at -1.000--0.500 EPS. As a group, equities research analysts anticipate that Medifast will post -2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Stephens dropped their target price on Medifast from $15.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, February 19th. Weiss Ratings restated a "sell (d)" rating on shares of Medifast in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Medifast from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $12.00.

Insider Activity

In other news, CEO Daniel R. Chard bought 17,678 shares of the stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of $10.11 per share, with a total value of $178,724.58. Following the purchase, the chief executive officer directly owned 17,678 shares in the company, valued at $178,724.58. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Medifast

A number of hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its holdings in Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer's stock valued at $8,297,000 after purchasing an additional 181,618 shares during the period. Bank of America Corp DE raised its stake in shares of Medifast by 14.2% during the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer's stock worth $6,186,000 after buying an additional 56,174 shares during the period. Lido Advisors LLC acquired a new position in shares of Medifast during the 3rd quarter worth approximately $4,521,000. Dimensional Fund Advisors LP lifted its position in shares of Medifast by 9.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer's stock valued at $3,484,000 after buying an additional 27,871 shares in the last quarter. Finally, Steamboat Capital Partners LLC purchased a new position in shares of Medifast during the 4th quarter valued at approximately $2,952,000. Hedge funds and other institutional investors own 95.51% of the company's stock.

About Medifast

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.